Medizen Humancare메디젠휴먼케어
236340 · KONEX · ₩236340 · 메디젠휴먼케어
- Market cap
- ₩4.1B
- Enterprise value
- —
- P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- ROE
- —
- Net margin
- —
Financial statements not available yet. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−66.4% from the high
₩1,233Today: ₩1,350 – ₩1,400₩4,015
Returns
- 1W−6.9%
- 1M−32.5%
- 3M−45.2%
- 6M−25.0%
- YTD−20.6%
- 1Y−25.0%
- Volume today
- 141
- 0.3× the 20-day average
- Traded today
- ₩191,200
- Listed shares
- 3,050,360
- EPS (12 months)
- —
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 30 of 100 (50 is a normal day for this stock).
- MomentumWeak-32.5% over the last month; the price is below its 20-day average.
Signals describe activity, not recommendations. Not financial advice.
Medizen Humancare stock overview
Medizen Humancare (메디젠휴먼케어, KRX: 236340) is listed on KONEX, in the Biotech & Pharma sector. The company operates in digital healthcare, a field that combines health services with medical IT to deliver personalized, precision-oriented medical care that aims to predict and prevent disease as well as treat it. Its shares closed at ₩1,350 on Oct 28, 2026, up 3.85% on the day, giving it a market value of ₩4.1B.
Key facts
- Market cap
- ₩4.1B
- Sector
- Biotech & Pharma
- Latest price change
- +3.85%
- As of
- Oct 28, 2026
- Main business
- The company operates in digital healthcare, a field that combines health services with medical IT to deliver personalized, precision-oriented medical care that aims to predict and prevent disease as well as treat it.
Quick answers about Medizen Humancare
- What does Medizen Humancare do?
- The company operates in digital healthcare, a field that combines health services with medical IT to deliver personalized, precision-oriented medical care that aims to predict and prevent disease as well as treat it. The business overview centers on the genomic analysis market, which uses sequencing and PCR technologies for diagnosis and disease prediction, including hereditary cancer testing, non-invasive prenatal testing, and direct-to-consumer genetic testing. The filing describes the industry context in Korea and globally, but the excerpt does not clearly state the company's own products, customers, or operating locations.
- What is the market cap of Medizen Humancare?
- The market capitalisation of Medizen Humancare was ₩4.1B at the close on Oct 28, 2026.
- Who are the largest shareholders of Medizen Humancare?
- According to the latest official filings, the largest reported holders are Daesang Well Life (8.62%, as of Dec 23, 2024).
- When is the next earnings report from Medizen Humancare?
- Korean companies rarely announce results dates in advance. Based on when Medizen Humancare filed the same report in past years, its next annual results is expected between Mar 20, 2027 and Mar 24, 2027.
Company profile
The company operates in digital healthcare, a field that combines health services with medical IT to deliver personalized, precision-oriented medical care that aims to predict and prevent disease as well as treat it. The business overview centers on the genomic analysis market, which uses sequencing and PCR technologies for diagnosis and disease prediction, including hereditary cancer testing, non-invasive prenatal testing, and direct-to-consumer genetic testing. The filing describes the industry context in Korea and globally, but the excerpt does not clearly state the company's own products, customers, or operating locations.
Written by AI from the company's latest annual report.
- Korean name
- 메디젠휴먼케어
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- CEO
- 신동직
- Founded
- Jul 2012
- Listed
- Jan 2016
- Listed shares
- 3,050,360
- Fiscal year ends
- Month 12
- Website
- www.medizencare.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent filings
See all- Investor relations (IR) eventOct 15, 2026
- Investor relations (IR) eventSep 18, 2026
- Exercise of Conversion Rights of Convertible SharesSep 17, 2026
- Investor relations (IR) eventMay 11, 2026
- Investor relations (IR) eventApr 14, 2026
Titles in Korean until English translations are added.
Also known as: Medizen Humancare / 메디젠휴먼케어 / 236340 / KRX:236340
Source: KRX statistical information